Condition

Anatomic Stage IIIA Breast Cancer AJCC v8

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 84 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials84

Recruiting11

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerNCT06324240 · 2025-12-02

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCNCT07016399 · 2025-09-09

Breast Cancer, Reasoning, and Activity InterventionNCT04816006 · 2024-02-22

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerNCT05417308 · 2023-03-01

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNCT04090567 · 2020-07-28

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast CancerNCT02918474 · 2017-04-28

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA TrialNCT07331077 · 2026-10-01

NOT_YET_RECRUITING

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast CancerNCT06538389 · 2024-08-26

STEMVAC in Patients With Early Stage Triple Negative Breast CancerNCT05455658 · 2022-11-17

ACTIVE_NOT_RECRUITING

Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer SurvivorsNCT05674578 · 2022-11-14

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast CancerNCT05368428 · 2022-10-19

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant ChemotherapyNCT04835597 · 2022-08-15

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast CancerNCT05244434 · 2022-07-03

Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer SurvivorsNCT04560439 · 2022-06-15

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer SurvivorsNCT05452681 · 2022-06-01

A Quality of Life Intervention for Young African American Breast Cancer Survivors in TreatmentNCT05243056 · 2022-06-01

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerNCT05319873 · 2022-04-07

ACTIVE_NOT_RECRUITING

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE StudyNCT04993313 · 2022-03-18

ACTIVE_NOT_RECRUITING

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerNCT05177796 · 2022-03-11

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer SurvivorsNCT07259304 · 2021-11-24

ACTIVE_NOT_RECRUITING

An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer SurvivorsNCT05012176 · 2021-11-01

Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast CancerNCT05086731 · 2021-10-22

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving PaclitaxelNCT04862585 · 2021-10-07

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer SurvivorsNCT04290897 · 2021-09-29

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal StudyNCT04754412 · 2021-07-23

ACTIVE_NOT_RECRUITING

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer SurvivorsNCT04906200 · 2021-06-28

ACTIVE_NOT_RECRUITING

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast CancerNCT04481113 · 2021-06-07

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast CancerNCT05071677 · 2021-05-03

Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung CancerNCT04705025 · 2021-04-08

Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer SurvivorsNCT04999826 · 2021-04-01

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider InterventionsNCT04549571 · 2021-02-16

ACTIVE_NOT_RECRUITING

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation TherapyNCT04927559 · 2020-12-18

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast CancerNCT04205903 · 2020-12-11

Nipple Aspirate Fluid in Detecting Breast CancerNCT03715959 · 2020-12-10

Exercise During Chemotherapy in Older Women With Stage I-III Breast CancerNCT05025059 · 2020-12-03

ACTIVE_NOT_RECRUITING

Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)NCT04537312 · 2020-11-17

ACTIVE_NOT_RECRUITING

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast CancerNCT04205071 · 2020-11-01

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast CancerNCT04535323 · 2020-09-23

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerNCT04249622 · 2020-09-18

RBX7455 Before Surgery for the Treatment of Operable Breast CancerNCT04139993 · 2020-08-31

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsNCT04216472 · 2020-07-10

Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and HandNCT04876378 · 2020-05-18

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast CancerNCT04294225 · 2020-04-28

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13

ACTIVE_NOT_RECRUITING

Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint TrialNCT04716920 · 2020-03-11

Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer SurvivorsNCT04200482 · 2020-02-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05

Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)NCT04866992 · 2020-02-01

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerNCT04249167 · 2020-01-23

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase InhibitorsNCT03953157 · 2019-10-07

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyNCT03872388 · 2019-09-23

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerNCT04001829 · 2019-08-09

ACTIVE_NOT_RECRUITING

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyNCT03707574 · 2019-07-16

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedNCT04185311 · 2019-07-10

Common interventions

Leading sponsors

M.D. Anderson Cancer Center21 Mayo Clinic11 Ohio State University Comprehensive Cancer Center11 Jonsson Comprehensive Cancer Center5 City of Hope Medical Center3 Emory University3 Fred Hutchinson Cancer Center3 National Cancer Institute (NCI)3 Alliance for Clinical Trials in Oncology2 ECOG-ACRIN Cancer Research Group2 OHSU Knight Cancer Institute2 SWOG Cancer Research Network2 Thomas Jefferson University2 University of Alabama at Birmingham2 University of California, San Francisco2

Trial status mix

COMPLETED34

ACTIVE_NOT_RECRUITING16

TERMINATED13

RECRUITING11

WITHDRAWN7

NOT_YET_RECRUITING1

SUSPENDED1

UNKNOWN1

Phase mix

NA30

PHASE220

PHASE119

EARLY_PHASE14

PHASE34

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.